

### AMENDMENTS TO THE CLAIMS

Claim 1 (Original): An isolated single-chain antibody that specifically binds to an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, and clone 1F3, wherein said antibody binds to and neutralizes botulinum neurotoxin type A (BoNT/A).

Claim 2 (Original): The antibody of claim 1, wherein said clone is S25.

Claim 3 (Original): The antibody of claim 1, wherein said clone is C25 or C39.

Claim 4 (Original): The antibody of claim 1, wherein said clone is 1C6.

Claim 5 (Original): The antibody of claim 1, wherein said clone is 1F3.

Claim 6 (Currently amended): The antibody of claim 1, wherein said antibody comprises at least two variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74),

Claim 7 (Currently amended): The antibody of claim 6, wherein said antibody comprises three variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74),

Claim 8 (Currently amended): The antibody of claim 1, wherein said antibody further comprises a variable light (VL) complementarity determining region (CDR) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or ~~nucleotides~~ amino acids 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or ~~nucleotides~~ amino acids 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or ~~nucleotides~~ amino acids 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 9 (Currently amended): The antibody of claim 8, wherein said antibody comprises at least two variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or ~~nucleotides~~ amino acids 24-33,

49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or ~~nucleotides~~amino acids 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or ~~nucleotides~~amino acids 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 10 (Currently amended): The antibody of claim 9, wherein said antibody comprises three variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or ~~nucleotides~~amino acids 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or ~~nucleotides~~amino acids 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or ~~nucleotides~~amino acids 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 11 (Original): The antibody of claim 1, wherein said antibody is an antibody expressed by a clone selected from the group consisting of a clone listed in Table 4.

Claim 12 (Original): The antibody of claim 1, wherein said antibody is a single chain Fv (scFv).

Claim 13 (Original): The antibody of claim 1, wherein said antibody is a Fab.

Claim 14 (Original): The antibody of claim 1, wherein said antibody is a (Fab')<sub>2</sub>.

Claim 15 (Original): The antibody of claim 1, wherein said antibody is a (scFv')<sub>2</sub>.

Claim 16 (Original): The antibody of claim 15, wherein said antibody is a fusion protein of two scFv fragments.

Claim 17 (Currently amended): The antibody of claim 1, wherein said antibody comprises a framework region listed in Table 4 (~~nucleotides~~amino acids 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74, ~~nucleotides~~amino acids 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, ~~nucleotides~~amino acids 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or ~~nucleotides~~amino acids 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

Claim 18 (Currently amended): The antibody of claim 17, wherein said framework is a variable heavy (VH) framework region listed in Table 4 (~~nucleotides~~ amino acids 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

Claim 19 (Currently amended): The antibody of claim 17, wherein said framework is a variable light (VL) framework region listed in Table 4 (~~nucleotides~~ amino acids 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, ~~nucleotides~~ amino acids 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or ~~nucleotides~~ amino acids 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

Claim 20 (Currently amended): The antibody of claim 18, wherein said antibody comprises at least two variable heavy (VH) framework regions listed in Table 4 (~~nucleotides~~ amino acids 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

Claim 21 (Currently amended): The antibody of claim 19, wherein said antibody comprises at least two variable light (VL) framework regions listed in Table 4 (~~nucleotides~~ amino acids 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, ~~nucleotides~~ amino acids 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or ~~nucleotides~~ amino acids 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

Claim 22 (Original): The antibody of claim 18, wherein said antibody comprises a variable heavy (VH) region listed in Table 4 (SEQ ID NOS:51-74).

Claim 23 (Original): The antibody of claim 19, wherein said antibody comprises a variable light (VL) region listed in Table 4 (SEQ ID NOS:75-98).

Claim 24 (Currently amended): (Once amended) An isolated single chain anti-botulinum neurotoxin type A (anti-BoNT/A) antibody, said antibody comprising a variable heavy (VH) complementarity determining region (CDR) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74), and wherein said antibody specifically binds to and neutralizes a botulinum neurotoxin type A.

Claim 25 (Currently amended): The antibody of claim 24, wherein said antibody comprises at least two variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74).

Claim 26 (Currently amended): The antibody of claim 25, wherein said antibody comprises at three variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74).

Claim 27 (Currently amended): The antibody of claim 24, wherein said antibody further comprises a variable light (VL) complementarity determining region (CDR) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or ~~nucleotides~~ amino acids 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or ~~nucleotides~~ amino acids 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or ~~nucleotides~~ amino acids 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 28 (Currently amended): The antibody of claim 27, wherein said antibody comprises at least two variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or ~~nucleotides~~ amino acids 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or ~~nucleotides~~ amino acids 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or ~~nucleotides~~ amino acids 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 29 (Currently amended): The antibody of claim 28, wherein said antibody comprises three variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (~~nucleotides~~ amino acids 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or ~~nucleotides~~ amino acids 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or ~~nucleotides~~ amino acids 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or ~~nucleotides~~ amino acids 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 30 (Original): The antibody of claim 24, wherein said antibody is an antibody expressed by a clone selected from the group consisting of a clone listed in Table 4.

Claim 31 (Original): The antibody of claim 24, wherein said antibody is a single chain Fv (scFv).

Claim 32 (Original): The antibody of claim 24, wherein said antibody is a Fab.

Claim 33 (Original): The antibody of claim 24, wherein said antibody is a (Fab')<sub>2</sub>.

Claim 34 (Original): The antibody of claim 24, wherein said antibody is a (scFv')<sub>2</sub>.

Claim 35 (Original): The antibody of claim 34, wherein said antibody is a fusion protein of two scFv fragments.

Claim 36 (Currently amended): The antibody of claim 24, wherein said antibody comprises a framework region listed in Table 4 (~~nucleotides~~ amino acids 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74, ~~nucleotides~~ amino acids 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, ~~nucleotides~~ amino acids 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or ~~nucleotides~~ amino acids 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

Claim 37 (Currently amended): The antibody of claim 36, wherein said framework is a variable heavy (VH) framework region listed in Table 4 (~~nucleotides~~ amino acids 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

Claim 38 (Currently amended): The antibody of claim 36, wherein said framework is a variable light (VL) framework region listed in Table 4 (~~nucleotides~~ amino acids 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, ~~nucleotides~~ amino acids 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, ~~nucleotides~~ amino acids 1-23, 39-53, 61-92, or 102-112 of any or SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 39 (Currently amended). The antibody of claim 37, wherein said antibody comprises at least two variable heavy (VH) framework regions listed in Table 4 (~~nucleotides~~ amino acids 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

Claim 40 (Currently amended): The antibody of claim 38, wherein said antibody comprises at least two variable light (VL) framework regions listed in Table 4 (~~nucleotides~~ amino acids 1-23, 34-48,

56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, ~~nucleotides~~amino acids 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, ~~nucleotides~~amino acids 1-23, 39-53, 61-92, or 102-112 of any or SEQ ID NOS: 80, 81, 84-87, or 92-95).

Claim 41 (Previously presented): The antibody of claim 37, wherein said antibody comprises a variable heavy (VH) region listed in Table 4 (SEQ ID NOS:51-74).

Claim 42 (Previously presented): The antibody of claim 38, wherein said antibody comprises a variable light (VL) region listed in Table 4 (SEQ ID NOS:75-98).

Claim 43 (Original): The antibody of claim 24, wherein antibody specifically binds to an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, and clone 1F3.

Claims 44-76 (Canceled).

Claim 77 (Currently amended): The antibody of claim 1, wherein said antibody comprises a variable heavy (VH) complementarity determining region (CDR) listed in Table 4 (~~nucleotides~~amino acids 31-35, 50-66, or 99-114 of any one of SEQ ID NOS:51-74).